RLAY News and Press, Relay Therapeutics Inc. From 05/04/23

Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clinical trial for RLY-5836, a chemically-distinct PI3Kα pan-mutant inhibitor $937.8 million in cash, cash equivalents and investments at end of Q...

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2023 financial...

2023-04-19 10:05:30 ET After losing over a third of the value in the previous session, Relay Therapeutics ( NASDAQ: RLAY ) added ~3% on Wednesday morning as Raymond James upgraded the biotech, noting that the selloff that followed initial clinical data for its cancer drug RL...

2023-04-19 08:38:04 ET Intuitive Machines ( LUNR ) +24% up 24% as JV with KBR bags a $719M NASA contract. VYNE Therapeutics  ( VYNE ) +21% a nnounces positive Preclinical data for inhaled formulation of VYN201 in an in Vivo model of idiopathic pulmonary fibrosis...

2023-04-18 13:00:45 ET Relay Therapeutics ( NASDAQ: RLAY ) stock fell ~30% on Tuesday after the company reported initial data for cancer drug RLY-2608. RLY-2608 is currently being evaluated in an ongoing dose-escalation portion of a study called ReDiscover. The mon...

2023-04-18 12:50:32 ET Gainers: BELLUS Health ( BLU ) +98% . Dermata Therapeutics ( DRMA ) +68% . Gamida Cell ( GMDA ) +53% . Allarity Therapeutics ( ALLR ) +45% . Esports Entertainment Group ( GMBL ) +35% . Altamira Therapeu...

Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at target exposures Confirmed partial response in breast cancer patient with...

2023-04-13 14:20:02 ET Relay Therapeutics ( NASDAQ: RLAY ) gained 14% on Thursday after Raymond James launched its coverage with an Outperform rating and a $29 per share target as the company prepares to release data for its cancer candidate RLY-2608 at an upcoming medical eve...

2023-04-09 12:00:00 ET The largest meeting in the world of cancer research is set to kick off this week. The annual meeting of the American Association for Cancer Research (AACR) is a much sought-after event in the healthcare calendar, with many pharma companies scheduled to highlight their...

2023-03-24 09:00:16 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group –  Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as ...